Bronchodilators, COPD
Therapeutic Class Review (TCR)
June 7, 2011

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Provider Synergies, L.L.C.

All requests for permission should be mailed to:

Attention: Copyright Administrator
Intellectual Property Department
Provider Synergies, L.L.C.
10101 Alliance Road, Suite 201
Cincinnati, Ohio 45242

The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to PSTCREditor@magellanhealth.com.
FDA-APPROVED INDICATIONS

<table>
<thead>
<tr>
<th>Drug</th>
<th>Manufacturer</th>
<th>Indication(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>albuterol/ipratropium inhalation solution (Duoneb&lt;sup&gt;®&lt;/sup&gt;&lt;sup&gt;1&lt;/sup&gt;)</td>
<td>generic</td>
<td>For the treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) in patients requiring more than one bronchodilator</td>
</tr>
<tr>
<td>albuterol/ipratropium MDI (Combivent&lt;sup&gt;®&lt;/sup&gt;)&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Boehringer-Ingelheim</td>
<td>For use in patients with COPD on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and require a second bronchodilator</td>
</tr>
<tr>
<td>ipratropium inhalation solution (Atrovent&lt;sup&gt;®&lt;/sup&gt;)&lt;sup&gt;3&lt;/sup&gt;</td>
<td>generic</td>
<td>For maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema</td>
</tr>
<tr>
<td>ipratropium inhalation aerosol MDI (Atrovent&lt;sup&gt;®&lt;/sup&gt; HFA)&lt;sup&gt;4&lt;/sup&gt;</td>
<td>Boehringer-Ingelheim</td>
<td>As a bronchodilator for maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema</td>
</tr>
<tr>
<td>roflumilast (Daliresp&lt;sup&gt;™&lt;/sup&gt;)&lt;sup&gt;5&lt;/sup&gt;</td>
<td>Forest Laboratories</td>
<td>As a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations</td>
</tr>
<tr>
<td>tiotropium inhalation powder DPI (Spiriva Handihaler&lt;sup&gt;®&lt;/sup&gt;)&lt;sup&gt;6&lt;/sup&gt;</td>
<td>Boehringer-Ingelheim</td>
<td>For the long-term, once-daily maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema To reduce COPD exacerbations</td>
</tr>
</tbody>
</table>

MDI=metered-dose inhaler  
DPI=dry powder inhaler

OVERVIEW

In the United States, chronic obstructive pulmonary disease (COPD) is the fourth leading cause of chronic morbidity and mortality.<sup>7</sup> COPD is a disease state characterized by the presence of airflow obstruction due to chronic bronchitis or emphysema. The airflow obstruction is generally progressive, may be accompanied by airway hyperreactivity, and may be partially reversible.<sup>8</sup>

Although the precise distinctions between chronic bronchitis and emphysema are a subject of debate, tradition holds that chronic bronchitis is responsible for 85 percent of COPD.<sup>9</sup> Patients with chronic bronchitis experience intermittent airway inflammation and excessive mucus production that leads to frequent, prolonged episodes of productive cough. In contrast, 15 percent of patients with COPD suffer primarily from emphysema. Emphysema is a disease in which destruction of the infrastructure of alveoli and distal airspaces, and thus the portion of the lung that provides gas exchange and elastic recoil, occurs.<sup>10</sup> The loss of alveolar walls results in decreased ventilation and a loss of the capillary network essential to perfusion.

Both chronic bronchitis and emphysema predispose patients to a common constellation of symptoms and to a collection of derangements in respiratory function. There are reductions in forced expiratory volume after one second (FEV<sub>1</sub>), forced vital capacity (FVC), FEV<sub>1</sub>/FVC ratio, and forced expiratory flow (FEF<sub>25-75%</sub>). The 2009 revised Executive Summary of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) COPD guidelines identify four stages of COPD severity based on post-bronchodilator FEV<sub>1</sub>: Stage 1 (Mild = FEV<sub>1</sub> ≥ 80% predicted), Stage 2 (Moderate = 50% ≤ FEV<sub>1</sub> < 80% predicted), Stage 3 (Severe = 30% predicted ≤ FEV<sub>1</sub> < 50% predicted), and Stage 4 (Very Severe = FEV<sub>1</sub> < 30% predicted or FEV<sub>1</sub> < 50% predicted plus the presence of chronic respiratory failure).<sup>11</sup> The American Thoracic
Society/European Respiratory Society (ATS/ERS) Guidelines include a 5th category, namely “At Risk”, which is based on FEV1 and risk factors including smoking or exposure to pollutants with cough, sputum, or dyspnea; or a family history of respiratory disease.12

Bronchodilator medications are central to the symptomatic management of COPD.13,14,15,16 They improve emptying of the lungs, tend to reduce dynamic hyperinflation at rest and during exercise, and improve exercise performance.17 They are given either on an as-needed basis for relief of persistent or worsening symptoms or on a regular basis to prevent or reduce symptoms. Regular treatment with long-acting bronchodilators is more effective and convenient than treatment with short-acting agents.18 Combining bronchodilators may improve efficacy and decrease the risk of side effects as compared to maximizing the dose of a single bronchodilator.19

The GOLD guidelines recommend a stepwise treatment plan for COPD based on disease severity.20 Bronchodilator medications are central to symptom management in COPD. For mild COPD, a short-acting bronchodilator used on an as-needed basis is recommended. For moderate and severe COPD, regular use of one or more long-acting bronchodilators is recommended. Long-acting inhaled bronchodilators are more effective and convenient than treatment with short-acting inhaled bronchodilators, but there is insufficient evidence to recommend one long-acting agent over another. The choice between a beta2 agonist, anticholinergic, theophylline, or combination therapy depends on individual response in terms of symptom relief and adverse effects.

In 2009, the updated GOLD guidelines were released and reiterated that beta2 agonist bronchodilators are among the principal treatments for symptomatic management of COPD.21 The guidelines state that patient care should be based on level of disease severity and clinical symptoms. The following medications are identified based on the likely order of introduction in treatment: short-acting beta agonists, long-acting beta agonists, short-acting anticholinergics, long-acting anticholinergics, combination short-acting beta agonist plus anticholinergic in one inhaler, methylxanthines, inhaled glucocorticoids, combination long-acting beta agonists plus glucocorticoids in one inhaler, and systemic glucocorticoids.

The American Thoracic Society (ATS) and European Respiratory Society (ERS) 2004 joint Standards for the Diagnosis and Management of COPD also recommend a similar stepwise treatment.22 For intermittent symptoms, an as-needed short-acting bronchodilator (beta2 agonist or anticholinergic) is recommended. For persistent symptoms, regular use of either a long-acting bronchodilator or a short-acting bronchodilator used four times daily, in addition to an as-needed agent (beta2 agonist), is recommended. If response to these measures is inadequate, consider an alternative class of bronchodilator or combination therapy. In addition, these guidelines state that combining short-acting agents (albuterol/ipratropium) produces a greater change in spirometry over three months than either agent alone. Combining long-acting inhaled beta-agonists and ipratropium leads to fewer exacerbations than either drug alone.23

Medications for COPD currently available can reduce or abolish symptoms, increase exercise capacity, reduce the number and severity of exacerbations, and improve health status. At present, no treatment is shown to modify the rate of decline in lung function.24 Included in this review is a new oral agent, roflumilast (Daliresp), which was FDA-approved in February 2011 as a treatment option in COPD management.25
PHARMACOLOGY

The anticholinergic agents, ipratropium (Atrovent) and tiotropium (Spiriva), antagonize the action of acetylcholine released from the vagus nerve. Inhibition of the muscarinic receptors blocks the cholinergic neurotransmission causing bronchodilation.

Tiotropium has similar affinity to the muscarinic receptor subtypes M1 to M5. Affinity to these receptors is six- to 20-fold greater than ipratropium. In the airways, tiotropium exhibits pharmacological effects through inhibition of M3-receptors at the smooth muscle. Tiotropium dissociates rapidly from M2 receptors (blockade of the specific M2 receptor causes an increase in the release of acetylcholine, which is an unwanted effect), but slowly from M1 and M3 receptors, resulting in prolonged bronchodilation.26

Roflumilast (Daliresp) and its active metabolite (roflumilast N-oxide) are selective inhibitors of phosphodiesterase 4 (PDE4). This action leads to the accumulation of cyclic adenosine monophosphate (cyclic AMP) in lung tissue. The specific mechanism by which roflumilast exerts its therapeutic action in patients with COPD still is not well-defined.27

PHARMACOKINETICS

<table>
<thead>
<tr>
<th>Drug</th>
<th>Onset of Action 15 percent or more increase in FEV₁ (hours)</th>
<th>Time to Peak FEV₁ (hours)</th>
<th>Duration of Action (hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>albuterol/ipratropium inhalation solution (Duoneb)³⁸</td>
<td>nr</td>
<td>1.5</td>
<td>4.3 - 5</td>
</tr>
<tr>
<td>albuterol/ipratropium MDI (Combivent)⁹⁹</td>
<td>0.25</td>
<td>1</td>
<td>4 - 5</td>
</tr>
<tr>
<td>ipratropium inhalation solution (Atrovent)³⁰</td>
<td>0.25 - 0.5</td>
<td>1 - 2</td>
<td>4 - 5 up to 7 - 8 in some patients</td>
</tr>
<tr>
<td>ipratropium inhalation aerosol MDI (Atrovent HFA)³¹</td>
<td>0.25</td>
<td>1 - 2</td>
<td>2 - 4</td>
</tr>
<tr>
<td>tiotropium inhalation powder (Spiriva)³²</td>
<td>0.5 (13 percent increase in FEV₁)</td>
<td>1 - 4</td>
<td>24</td>
</tr>
</tbody>
</table>

nr = not reported

Bronchodilation following inhalation of these agents is a local, site-specific effect. It is important to note that roflumilast (Daliresp) is not a bronchodilator.³³

Although much of an administered dose of ipratropium (Atrovent) and tiotropium (Spiriva) is swallowed, since they are quaternary amines, minimal drug is absorbed from the gastrointestinal (GI) tract is expected. Ipratropium is poorly absorbed from the lungs while tiotropium is highly bioavailable from the lung surface (19.5 percent absolute bioavailability).³⁴,³⁵

Fourteen percent of an inhaled dose of tiotropium is excreted unchanged in the urine. Renal impairment is associated with increased tiotropium concentrations after dry powder inhalation. Approximately 25 percent of an absorbed tiotropium dose is metabolized via the cytochrome P450
system. Inhibitors of CYP450 3A4 or 2D6 such as ketoconazole or quinidine may impact tiotropium metabolism.\textsuperscript{36}

The terminal elimination half-life of tiotropium is between five and six days, and after once daily inhalation by COPD patients, steady state was reached after two to three weeks.\textsuperscript{37}

The absolute bioavailability of roflumilast following a 500 microgram oral dose is approximately 80 percent. Plasma protein binding of roflumilast and its N-oxide metabolite is approximately 99 percent and 97 percent, respectively. Following an oral dose, the median plasma half-life of roflumilast and its N-oxide metabolite are approximately 17 and 30 hours, respectively. Roflumilast is extensively metabolized via Phase I (cytochrome P450) and Phase II (conjugation) reactions. Steady state plasma concentrations of roflumilast and its N-oxide metabolite are reached after approximately four days for roflumilast and six days for roflumilast N-oxide following once daily dosing.\textsuperscript{38}

**CONTRAINDICATIONS/WARNINGS**\textsuperscript{39,40,41,42,43,44,45}

Patients with a history of hypersensitivity to atropine or any of its derivatives (e.g. ipratropium) should not use any of these products.

Albuterol/ipratropium MDI (Combivent) is contraindicated in patients with a history of hypersensitivity to soy lecithin or related food products such as soybean or peanut.

Tiotropium inhalation powder (Spiriva) is not indicated for the initial treatment of acute episodes of bronchospasm, e.g., rescue therapy. In addition, immediate hypersensitivity reactions, including angioedema may occur after administration. If such a reaction occurs, therapy should be stopped at once, and alternative treatments should be considered.

Roflumilast (Daliresp) is contraindicated for use in patients with moderate to severe liver impairment (Child-Pugh B or C).

Inhaled medicines may cause paradoxical bronchospasm, which may be life-threatening. If this occurs, treatment with any of these products should be stopped and other alternatives considered.

**DRUG INTERACTIONS**\textsuperscript{46,47,48,49,50,51,52}

Monoamine oxidase (MAO) inhibitors and tricyclic antidepressants should be used cautiously with albuterol-containing products like albuterol/ipratropium inhalation solution (Duoneb) and albuterol/ipratropium MDI (Combivent) due to the potentiation of cardiovascular effects. A two-week discontinuation period of the MAO inhibitors and tricyclic antidepressants is suggested prior to initiating therapy with an albuterol-containing product.

Use with inhibitors of CYP3A4 or dual inhibitors of CYP3A4 and CYP1A2 (e.g., erythromycin, ketoconazole, fluvoxamine, cimetidine) will increase roflumilast (Daliresp) systemic exposure and may result in increased adverse reactions. The risk of such concurrent use should be weighed carefully against benefit.
ADVERSE EFFECTS

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dry Mouth</th>
<th>Head-ache</th>
<th>Nausea / Vomiting</th>
<th>Nervousness</th>
<th>Palpitations / Chest Pain</th>
<th>Tremor</th>
</tr>
</thead>
<tbody>
<tr>
<td>albuterol/ ipratropium inhalation solution (Duoneb)</td>
<td>nr</td>
<td>nr</td>
<td>1.4</td>
<td>nr</td>
<td>2.6</td>
<td>nr</td>
</tr>
<tr>
<td>albuterol/ ipratropium MDI (Combivent)</td>
<td>≤ 2</td>
<td>5.6</td>
<td>≤ 2</td>
<td>&lt; 2</td>
<td>0.3</td>
<td>&lt; 2</td>
</tr>
<tr>
<td>ipratropium inhalation solution (Atrovent)</td>
<td>3.2</td>
<td>6.4</td>
<td>4.1</td>
<td>0.5</td>
<td>reported</td>
<td>0.9</td>
</tr>
<tr>
<td>ipratropium aerosol MDI (Atrovent HFA)</td>
<td>2-4</td>
<td>6-7</td>
<td>4</td>
<td>nr</td>
<td>reported</td>
<td>nr</td>
</tr>
<tr>
<td>roflumilast (Daliresp)</td>
<td>nr</td>
<td>4.4</td>
<td>4.7</td>
<td>nr</td>
<td>reported</td>
<td>1 - 2</td>
</tr>
<tr>
<td>tiotropium inhalation powder DPI (Spiriva)</td>
<td>12-16</td>
<td>nr</td>
<td>1-4</td>
<td>nr</td>
<td>5-7</td>
<td>nr</td>
</tr>
</tbody>
</table>

Adverse effects are reported as a percentage. Adverse effects data are obtained from package inserts and are not meant to be comparative or all-inclusive. nr = not reported.

The most common adverse event reported with tiotropium was dry mouth (16 percent). Other reports of adverse events with tiotropium are consistent with anticholinergic effects including constipation (four percent), blurred vision, and new onset or worsening of glaucoma (percentages not reported), and urinary retention or difficulty (less than one percent).

In one trial that enrolled 198 COPD patients, the number of patients with changes from baseline-corrected QT interval of 30 – 60 msec was higher in the tiotropium-treated group (range 16 to 20 percent) as compared to the placebo group (range one to 12 percent) depending on QT correction method used. Other clinical studies did not detect a drug effect on QTc intervals.

A FDA MedWatch was issued on March 19, 2008 related to an ongoing safety review of tiotropium and its potential to increase the risk of stroke in patients. The information is based on data submitted by the manufacturer, Boehringer Ingelheim, from a pooled analysis of 29 placebo-controlled trials with 13,500 patients with COPD. The preliminary estimate of eight strokes per 1,000 patients treated annually with tiotropium is higher than the six strokes per 1,000 patients treated annually with placebo. However, on January 14, 2010, the FDA completed its review and issued a statement that the available data do not support the association between Spiriva use and an increase risk for stroke, myocardial infarction, or death from a cardiovascular event. Healthcare professionals are recommended to continue to prescribe Spiriva as directed by the prescribing information.

The two most common adverse events reported with roflumilast were diarrhea (9.5 percent) and weight loss (7.5 percent).

Monitoring

Anticholinergic drugs may worsen symptoms associated with narrow-angle glaucoma, prostatic hyperplasia, or bladder neck obstruction.
Tiotropium is a predominantly renally excreted drug. Patients with moderate-to-severe renal impairment (creatinine clearance less or equal to 50 mL per minute) should be monitored closely. 62

Roflumilast has been associated with decreased weight so patients using this drug should have their weight monitored regularly. If unexplained or clinically significant weight loss occurs, an evaluation should be conducted and discontinuation of the drug should be considered. 63

SPECIAL POPULATIONS 64,65,66,67,68,69,70

Pediatrics
COPD is a disease that does not normally occur in children. Safety and effectiveness of ipratropium (Atrovent), albuterol/ipratropium MDI (Combivent), albuterol/ipratropium inhalation solution (Duoneb), roflumilast (Daliresp) and tiotropium DPI (Spiriva) in pediatric patients have not been established.

Pregnancy
Albuterol, albuterol/ipratropium MDI, albuterol/ipratropium inhalation solution, roflumilast, and tiotropium are Pregnancy Category C. Ipratropium is Category B.

Other considerations – renal, hepatic, race, etc.
The pharmacokinetics of albuterol/ipratropium (Combivent) have not been studied in patients with renal insufficiency, hepatic insufficiency, or the elderly.

The pharmacokinetics of ipratropium as not been studied in patients with renal or hepatic insufficiency.

Since tiotropium is predominantly renally excreted, renal impairment was associated with increased plasma drug concentrations and reduced drug clearance. Patients with moderate to severe renal impairment (creatinine clearance of ≤50 mL/min) should be monitored closely for anticholinergic side effects when treated with tiotropium.

An eight-week, randomized, double-blind, placebo-controlled trial was conducted in 166 African-Americans with COPD to determine the efficacy of once daily inhaled tiotropium versus placebo. 71 The primary efficacy endpoint was the FEV₁ AUC (0-3) after eight weeks of therapy. A total of 160 patients were eligible for efficacy evaluation. At the end of the study period, the tiotropium group (n=78) had a FEV₁ AUC (0-3) of 180 mL greater than the placebo group (n=82; p<0.0001). There were no significant differences in use of rescue medications between the two groups. Also, there were no patients in the tiotropium group who experienced a COPD exacerbation while there were 12 patients in the placebo group who did. This study was sponsored and conducted by the manufacturer of tiotropium (Spiriva).

No dosage adjustment of roflumilast is necessary in patients with renal impairment. Roflumilast is not recommended for use in patients with moderate to severe liver impairment (Child-Pugh B or C).
DOSAGES

<table>
<thead>
<tr>
<th>Drug</th>
<th>Adult Dose</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>albuterol sulfate /ipratropium bromide inhalation solution (Duoneb&lt;sup&gt;®&lt;/sup&gt;)&lt;sup&gt;72&lt;/sup&gt;</td>
<td>3 mL four times daily (up to two additional 3 mL doses per day)</td>
<td>3 mg / 0.5 mg per 3 mL</td>
</tr>
<tr>
<td>albuterol/ipratropium bromide MDI (Combivent&lt;sup&gt;®&lt;/sup&gt;)&lt;sup&gt;73&lt;/sup&gt;</td>
<td>Two inhalations four times daily (do not exceed 12 inhalations in 24 hours)</td>
<td>90 mcg / 18 mcg per actuation</td>
</tr>
<tr>
<td>ipratropium bromide inhalation solution (Atrovent)&lt;sup&gt;74&lt;/sup&gt;</td>
<td>2.5 mL three to four times daily</td>
<td>500 mcg per 2.5 mL</td>
</tr>
<tr>
<td>ipratropium inhalation aerosol MDI (Atrovent HFA)&lt;sup&gt;75&lt;/sup&gt;</td>
<td>Two inhalations four times daily (do not exceed 12 inhalations in 24 hours)</td>
<td>17 mcg per actuation</td>
</tr>
<tr>
<td>roflumilast (Daliresp)&lt;sup&gt;76&lt;/sup&gt;</td>
<td>One tablet (500 micrograms) daily, with or without food</td>
<td>Tablets: 500 mcg</td>
</tr>
<tr>
<td>tiotropium inhalation powder DPI (Spiriva Handihaler&lt;sup&gt;®&lt;/sup&gt;)&lt;sup&gt;77&lt;/sup&gt;</td>
<td>One inhalation daily</td>
<td>18 mcg per capsule</td>
</tr>
</tbody>
</table>

MDI=metered-dose inhaler  
DPI=dry powder inhaler

An FDA Public Health Advisory was issued in March 2008 to highlight the correct use of tiotropium (Spiriva) capsules, which are to be used in the Handihaler device. These capsules should not be swallowed.  

CLINICAL TRIALS

Search Strategy

Articles were identified through searches performed on PubMed and review of information sent by manufacturers. Search strategy included the FDA-approved use of all drugs in this class. Randomized, controlled, comparative trials are considered the most relevant in this category. Studies included for analysis in the review were published in English, performed with human participants, and randomly allocated participants to comparison groups. In addition, studies must contain clearly stated, predetermined outcome measure(s) of known or probable clinical importance, use data analysis techniques consistent with the study question, and include follow-up (endpoint assessment) of at least 80 percent of participants entering the investigation. Despite some inherent bias found in all studies including those sponsored and/or funded by pharmaceutical manufacturers, the studies in this therapeutic class review were determined to have results or conclusions that do not suggest systematic error in their experimental study design. While the potential influence of manufacturer sponsorship/funding must be considered, the studies in this review have also been evaluated for validity and importance.

albuterol MDI (Proventil, Ventolin) + ipratropium MDI (Atrovent) versus formoterol DPI (Foradil) + ipratropium MDI (Atrovent)

A large, randomized, double-blind, double-dummy, two-period crossover study of 172 patients with COPD investigated the effects of the addition of either formoterol or albuterol to ipratropium in patients whose symptoms were not optimally controlled by ipratropium alone. In addition to ipratropium MDI 40 mcg four times daily, patients received, in random order, formoterol DPI 12 mcg
twice daily for three weeks followed by albuterol MDI 200 mcg four times daily for three weeks, or vice versa. Morning peak expiratory flow rate (PEFR) and FEV<sub>1</sub> were significantly better with the formoterol- 
ipratropium combination than with the albuterol-irapratropium combination (p=0.0003 and p<0.0001 for PEFR and FEV<sub>1</sub>, respectively). Similar findings were noted for FVC. On average, all mean individual symptom scores were lower for patients receiving the formoterol-irapratropium combination than for those receiving the albuterol-irapratropium combination (p=0.0042). There were no significant differences between the formoterol and albuterol groups in mean percentage of days with no rescue drug (72.3 and 68.8 percent, respectively), the number of patients with no COPD exacerbations (34.6 and 30.8 percent, respectively), or the percentage of patients experiencing "bad days" during the trial (65 and 69 percent, respectively).

**roflumilast (Daliresp) versus placebo**

The efficacy and safety of roflumilast in COPD was evaluated in eight randomized double-blind, 
controlled, parallel group clinical trials in 9,394 adult patients (4,425 receiving roflumilast 500 mcg) 
who were 40 years of age and older with COPD. Of the eight trials, two were placebo-controlled dose 
selection trials (Trials 1 and 2) of six months duration that evaluated the efficacy of roflumilast 250 mcg 
and 500 mcg once daily, four were placebo-controlled one-year trials (Trials 3, 4, 5, and 6) primarily 
designed to evaluate the efficacy of roflumilast on COPD exacerbations, and two were six-month 
efficacy trials (Trials 7 and 8) which assessed the effect of roflumilast as add-on therapy to a long-
acting beta agonist or long-acting anti-muscarinic agent. No trials have been conducted to assess the 
effects of roflumilast on COPD exacerbations when added to a fixed-dose combination product 
containing a long-acting beta agonist and inhaled corticosteroid.

**tiotropium (Spiriva) versus placebo**

The Understanding the Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) trial was a 
large, randomized, double-blind, placebo-controlled trial that compared four years of therapy with 
either tiotropium or placebo in 5,993 patients with COPD who were permitted to use all respiratory 
medications except inhaled anticholinergic drugs. The patients were at least 40 years of age with an 
FEV<sub>1</sub> of 70 percent or less after bronchodilation and a ratio of FEV<sub>1</sub> to FVC of 70 percent or less. The 
objective of the study was to determine whether treatment with tiotropium 18 mcg reduced the rate 
of decline of FEV<sub>1</sub> over time in patients with COPD. The two co-primary end points were the yearly rate 
of decline in the mean FEV<sub>1</sub> before the use of a study drug and short-acting bronchodilators in the 
morning (pre-bronchodilator) and after the use of a study drug (post-bronchodilator) from day 30 
(steady state) until completion of double-blind treatment. Secondary endpoints included measures of 
rates of mean decline for both FVC and slow vital capacity (SVC), health-related quality of life as 
measured by the total score on St. George's Respiratory Questionnaire (SGRQ), exacerbations of COPD, 
and mortality. Patients were randomly assigned to the tiotropium group (n=2,987) or to the placebo 
group (n=3,006). Mean absolute improvements in FEV<sub>1</sub> in the tiotropium group were maintained 
throughout the trial (ranging from 87 to 103 mL before bronchodilation and from 47 to 65 mL after 
bronchodilation), as compared with the placebo group (p<0.001). After day 30, the differences 
between the two groups in the rate of decline in the mean FEV<sub>1</sub> at any time point were not significant. 
The mean absolute total score on the SGRQ was lower, indicating improvement, in the tiotropium 
group compared with the placebo group at each time point throughout the four-year period (p<0.001). 
At four years and 30 days, tiotropium treatment was associated with a reduction in the risks of
exacerbations, related hospitalizations, and respiratory failure, but tiotropium did not significantly reduce the rate of decline in FEV\textsubscript{1}.

In a subgroup analysis of the UPLIFT trial, data from 2,739 participants diagnosed with COPD (GOLD stage II) were examined.\textsuperscript{82} The tiotropium group had a statistically insignificant lower decline of pre-bronchodilator FEV\textsubscript{1} than the control group (35 mL per year versus 37 mL per year, p=0.38) and lower post-bronchodilator FEV\textsubscript{1} (43 mL per year versus 49 mL per year, p=0.024). SGRQ scores were lower in tiotropium group than the control group (p≤0.006 for all time points), indicating a statistically significant, improved health status. Mean number of exacerbations was lower in the tiotropium group than the control group (0.56 per patient-year versus 0.70 per patient-year, p<0.0001). The results of this subgroup analysis provided further support for the rationale of starting a long-acting anticholinergic in patients with moderate COPD.

tiotropium (Spiriva) versus albuterol/ipratropium MDI (Combivent)

A parallel group, double-blind, double-dummy randomized controlled trial was conducted in 676 patients with moderate to very severe stable COPD (mean FEV\textsubscript{1} of 39 percent predicted) over an 84 day period to determine if patients already receiving albuterol/ipratropium combination four times daily could use tiotropium once daily as a potential alternative.\textsuperscript{83} Patients were randomized to receive either tiotropium 18 mcg each morning or continue with albuterol 206 mcg/ipratropium 26 mcg using two actuations four times daily. A six-hour spirometry assessment was conducted on study days one, 22, and 84. In terms of primary outcomes, mean trough FEV\textsubscript{1} at 84 days was larger in the tiotropium arm compared to the combination arm (difference=86 mL; 95% CI, 49 to 123 mL, p<0.0001). However, the six hour spirometry assessments during the trial only confirmed non-inferiority of the two treatments (p<0.0001) and did not show superiority of tiotropium to the combination (p=0.37). Lower respiratory adverse events were reported in 40 tiotropium patients compared to 52 patients receiving the combination. Otherwise, safety reporting was similar for the two groups. The authors concluded that patients previously maintained on albuterol/ipratropium combination taken four times daily can be switched to tiotropium once daily with the reasonable expectation of at least equivalent bronchodilation during daytime hours.

tiotropium (Spiriva) versus ipratropium (Atrovent)

The Dutch Tiotropium Group evaluated and compared the efficacy and safety of tiotropium and ipratropium during long-term treatment of patients with stable COPD.\textsuperscript{84} Two-hundred eighty-eight patients with mean age 65 years and mean FEV\textsubscript{1} 41 percent of predicted value participated in a 14-center, double-blind, double-dummy, parallel group study. Patients were randomized to receive either tiotropium 18 mcg once daily from a dry powder inhaler (HandiHaler; two thirds of patients) or ipratropium 40 mcg four times daily from a metered dose inhaler (one third of patients) for 13 weeks. Outcome measures were lung function, daily records of PEF, and the use of concomitant albuterol. During treatment, tiotropium achieved a significantly greater improvement than ipratropium in trough, average, and peak FEV\textsubscript{1} levels, trough and average FVC levels, and weekly mean morning and evening PEF. The use of concomitant albuterol was also significantly lower in the tiotropium group (p<0.05). The only drug related adverse event was dry mouth (tiotropium 14.7 percent versus ipratropium 10.3 percent).

Two, one-year, randomized, double-blind, double-dummy studies evaluated tiotropium 18 mcg once daily (n=356) with ipratropium 40 mcg four times daily (n=179).\textsuperscript{85} Mean baseline FEV\textsubscript{1} values were 41.9
percent of predicted value for tiotropium and 39.4 percent of predicted value for ipratropium. Trough FEV\textsubscript{1} at one year improved by 0.12 +/- 0.01 L with tiotropium and declined by 0.03 +/- 0.02 L with ipratropium (p<0.001). Tiotropium reduced the number of exacerbations by 24 percent (p<0.01), increased time to first exacerbation (p<0.01), and the time to first hospitalization for a COPD exacerbation (p<0.05) compared with ipratropium. Apart from an increased incidence of dry mouth in the tiotropium group, adverse events were similar between treatments.

**tiotropium (Spiriva) versus salmeterol (Serevent)**

A six-month, randomized, placebo-controlled, double-blind, double-dummy, parallel-group study in 623 patients (tiotropium, n=209; salmeterol, n=213; and placebo, n=201) evaluated tiotropium 18 mcg once daily via dry-powder inhaler compared with salmeterol 50 mcg twice daily via metered dose inhaler. The study was conducted in patients with a baseline mean FEV\textsubscript{1} 40 percent of predicted value and a mean age of 65 years.\textsuperscript{86} Compared with placebo treatment, the mean predose morning FEV\textsubscript{1} following six months of therapy increased significantly more for the tiotropium group (0.14 L) than the salmeterol group (0.09 L) (p<0.01). The difference between tiotropium and salmeterol was statistically significant (0.05 L; p<0.01). At study end, trough FVC had improved significantly above placebo at 0.25 L for tiotropium (p<0.001) and 0.13 L for salmeterol (p<0.001). The difference between tiotropium and salmeterol was 0.11 L (p<0.01). Both active drugs significantly reduced the need for rescue albuterol. Tiotropium patients also achieved meaningful changes in health related quality of life compared to salmeterol patients.

Patients with COPD (tiotropium, n=402; salmeterol, n=405; placebo, n=400) were enrolled in two, six-month, randomized, placebo controlled, double-blind, double-dummy studies of tiotropium 18 mcg once daily via HandiHaler or salmeterol 50 mcg twice daily via a metered dose inhaler.\textsuperscript{87} The two trials were combined for analysis of health outcomes consisting of exacerbations, health resource use, dyspnea (assessed by the transitional dyspnea index, TDI), health-related quality of life (assessed by St. George's Respiratory Questionnaire [SGRQ]), and spirometry. Compared with placebo, tiotropium, but not salmeterol, was associated with a significant delay in the time to onset of the first exacerbation. Fewer COPD exacerbations per patient year occurred in the tiotropium group (1.07 events/year), than in the salmeterol group (1.23 events/year, p=0.222) or in the placebo group (1.49 events/year, p<0.05). The tiotropium group had 0.10 hospital admissions per patient year for COPD exacerbations compared with 0.17 for salmeterol and 0.15 for placebo (p=NS). SGRQ total scores improved by 4.2, 2.8, and 1.5 units during the six-month trial for the tiotropium, salmeterol, and placebo groups, respectively (p<0.01 tiotropium versus placebo). Compared with placebo, TDI focal score improved in both the tiotropium group (1.1 units, p<0.001) and the salmeterol group (0.7 units, p<0.05). The difference between tiotropium and salmeterol was not significant (p=0.17).

**tiotropium (Spiriva) + placebo versus tiotropium (Spiriva) + salmeterol (Serevent) OR fluticasone/salmeterol (Advair\textsuperscript{®})**

A randomized, double-blind, placebo-controlled trial was conducted in Canada with 449 patients with moderate to severe COPD who had one year of treatment with tiotropium plus placebo, tiotropium plus salmeterol, or tiotropium plus fluticasone/salmeterol.\textsuperscript{88} The proportion of patients in the tiotropium plus placebo group who had episodes of an exacerbation (62.8 percent) was not different from that in the tiotropium plus salmeterol group (64.8 percent; [95% CI, −12.8 to 8.8]) or in the tiotropium plus fluticasone/salmeterol group (60 percent; [95% CI, −8.2 to 13.8 percentage points]).
Tiotropium plus fluticasone/salmeterol improved lung function as measured by FEV₁ (p=0.049) and disease-specific quality of life (p=0.01), reduced the number of hospitalizations for COPD exacerbation (incidence rate ratio, 0.53 [95% CI, 0.33 to 0.86]) as well as all-cause hospitalizations (incidence rate ratio, 0.67 [95% CI, 0.45 to 0.99]) compared with tiotropium plus placebo. In contrast, tiotropium plus salmeterol did not statistically improve lung function or hospitalization rates compared with tiotropium plus placebo. It is noteworthy that more than 40 percent of patients who received tiotropium plus placebo and tiotropium plus salmeterol discontinued therapy prematurely, and many crossed over to treatment with open-label inhaled corticosteroids or long-acting beta-agonists. The authors concluded that the addition of fluticasone/salmeterol to tiotropium therapy did not statistically influence rates of COPD exacerbation but did improve lung function, quality of life, and hospitalization rates in patients with moderate to severe COPD.

**tiotropium (Spiriva) versus tiotropium (Spiriva) + formoterol (Foradil)**

In a 12-week active-controlled, double-blind, multicenter trial, a total of 255 subjects with COPD were randomized to either a combination of formoterol 12 mcg twice daily plus tiotropium 18 mcg once daily in the morning or monotherapy with tiotropium 18 mcg once daily in the morning. The primary efficacy variable was the area under the curve for forced expiratory volume in one second measured zero to four hours after the morning dosing (FEV₁ AUC₀⁻⁴h). Significantly greater improvements in the FEV₁ AUC₀⁻⁴h were seen with formoterol plus tiotropium versus tiotropium alone at all time points. At endpoint, FEV₁ AUC₀⁻⁴h increased 340 mL with formoterol plus tiotropium versus 170 mL with tiotropium alone (p<0.001). Improvements in trough FEV₁ with formoterol plus tiotropium versus tiotropium alone were 180 mL and 100 mL, respectively (p<0.01). Significantly greater reductions from baseline in symptom scores (p<0.05) and daytime albuterol use (p<0.04) were seen at endpoint with combination formoterol plus tiotropium versus tiotropium monotherapy. Both treatments were well tolerated.

**META-ANALYSES**

A 2008 meta-analysis of 17 randomized, controlled trials of 14,783 patients was conducted to ascertain the cardiovascular risks including cardiovascular death, myocardial infarction (MI), and stroke of inhaled anticholinergics (tiotropium or ipratropium bromide) versus control therapy (inhaled salmeterol, inhaled salmeterol/fluticasone, inhaled albuterol, or placebo). The study selection included trials of at least 30 days duration and reported on cardiovascular events. The primary outcome was a composite of cardiovascular death, MI, or stroke. The secondary outcome was all-cause mortality. The authors state that cardiovascular death is a more frequent cause of death in patients with COPD than respiratory causes. Based on the results, inhaled anticholinergics significantly increased the risk of the composite outcome of cardiovascular death, MI or stroke (1.8 percent versus 1.2 percent for control; p<0.001). Further delineation for individual primary outcomes were also assessed and showed inhaled anticholinergics significantly increased the risk of MI (1.2 percent versus 0.8 percent, p=0.03) based on eleven trials involving 10,598 patients. Risk of cardiovascular death was significantly increased by inhaled anticholinergics (0.9 percent versus 0.5 percent, p=0.008) in twelve trials of 12,376 patients. On the other hand, inhaled anticholinergics did not significantly increase the risk of stroke (0.5 percent versus 0.4 percent for control, p=0.20). Inhaled anticholinergics also did not significantly increase the risk of all-cause mortality (2 percent versus 1.6 percent; p=0.06). Important to note in the meta-analysis is that many of the trials included were small and short-term, none of them were specifically designed to monitor risk of cardiovascular events, and some of the reporting of
cardiovascular outcomes may have been incomplete. Further prospective studies that are adequately powered are needed to assess the cardiovascular safety of the inhaled anticholinergics. In the meantime, the risks of adverse events (e.g., MI or cardiovascular death) versus benefits of symptomatic improvement (e.g., increase in exercise capacity, reduced COPD exacerbations and hospitalizations, and improved dyspnea) must be weighed when using the inhaled anticholinergics. Unfortunately, alternative therapeutic options are limited for patients with COPD due to their differing adverse effect profiles.

Results from a systematic search including studies from MEDLINE and the Cochrane databases between 1966 and March 2007 on inhaled therapies and disease management were used to determine the effectiveness of management strategies for COPD (including inhaled therapies) in regards to exacerbations, hospitalization, and deaths, and adverse effects. Treatment was recommended for patients with stable COPD who have respiratory symptoms and FEV<sub>1</sub>&lt;60. Treatment should consist of one of the following: long-acting inhaled beta-agonist, long-acting inhaled anticholinergic, or inhaled corticosteroid. There was insufficient documentation to recommend one monotherapy over another since they had similar effectiveness although different adverse effects, reductions in deaths, and hospitalizations were observed. Studies of combination therapies do not consistently show benefits of combination therapy over monotherapy.

More questions will be generated as a result of a meta-analysis of 22 randomized, double-blind, placebo or active-controlled trials with 15,276 patients. The meta-analysis evaluated the safety and efficacy of anticholinergics (ipratropium and tiotropium) and beta<sub>2</sub> agonists (albuterol, metaproterenol, formoterol, and salmeterol) in COPD. Anticholinergics significantly reduced severe COPD exacerbations compared to placebo as well as reduced respiratory deaths. On the contrary, beta<sub>2</sub> agonists did not affect severe COPD exacerbations and actually increased the rate of respiratory deaths compared with placebo.

**SUMMARY**

COPD is categorized in Stages: I (mild), II (moderate), III (severe), and IV (very severe). Treatment initiation may begin with use of as-needed short-acting bronchodilators followed by routine long-acting bronchodilators, inhaled corticosteroids, long-term oxygen therapy, and even surgery. Regular use of long-acting beta agonists or short- or long-acting anticholinergics has been shown to improve health status.

Albuterol is available in combination with ipratropium in both a MDI (Combivent) and as inhalation solution (Duoneb) for the treatment of COPD. The combination MDI may be beneficial in reducing the number of puffs per day required as compared to treatment with the individual components.

The two anticholinergic options in this class are ipratropium (Atrovent) and tiotropium (Spiriva). The long-acting, anticholinergic agent, tiotropium, is dosed once daily and has a duration of action greater than 24 hours. Both agents have been shown to improve bronchodilation, dyspnea, exacerbation rates, and health-related quality of life. Adverse effects are limited primarily to dry mouth that appears to resolve with continued use.

Roflumilast (Daliresp) is the first and only selective phosphodiesterase-4 (PDE4) inhibitor to be FDA-approved in February 2011 as a treatment option in COPD management. Unlike the other inhaled treatment options currently available, roflumilast is an oral tablet formulation taken once daily. Roflumilast is not a bronchodilator and is not indicated for the relief of acute bronchospasm. COPD
exacerbations are a leading cause of hospitalization and mortality. The role of roflumilast in the comprehensive management of COPD remains to be fully elucidated.33

REFERENCES

2. Combivent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; April 2011.
3. Atrovent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; March 2002.
5. Daliresp [package insert]. St. Louis, MO; Forest Laboratories; February 2011.
25. Daliresp [package insert]. St. Louis, MO; Forest Laboratories; February 2011.
27. Daliresp [package insert]. St. Louis, MO; Forest Laboratories; February 2011.
29. Combivent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; April 2011.
32. Spiriva [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; December 2009.
33. Daliresp [package insert]. St. Louis, MO; Forest Laboratories; February 2011.
34. Atrovent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; March 2002.
35. Spiriva [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; December 2009.
37. Spiriva [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; December 2009.
38. Daliresp [package insert]. St. Louis, MO; Forest Laboratories; February 2011.
48 Atrovent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; March 2002.
49 Atrovent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; March 2002.
50 Atrovent HFA [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; December 2010.
51 Spiriva [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; December 2009.
52 Daliresp [package insert]. St. Louis, MO; Forest Laboratories; February 2011.
53 DuoNeb [package insert]. Napa, CA; Dey; March 2011.
54 Combivent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; April 2011.
55 Atrovent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; March 2002.
56 Atrovent HFA [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; December 2010.
57 Daliresp [package insert]. St. Louis, MO; Forest Laboratories; February 2011.
58 Spiriva [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; December 2009.
59 Spiriva [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; December 2009.
61 Daliresp [package insert]. St. Louis, MO; Forest Laboratories; February 2011.
62 Spiriva [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; December 2009.
63 Daliresp [package insert]. St. Louis, MO; Forest Laboratories; February 2011.
64 DuoNeb [package insert]. Napa, CA; Dey; March 2011.
65 Combivent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; April 2011.
66 Atrovent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; March 2002.
67 Atrovent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; March 2002.
68 Atrovent HFA [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; December 2010.
69 Spiriva [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; December 2009.
70 Daliresp [package insert]. St. Louis, MO; Forest Laboratories; February 2011.
72 DuoNeb [package insert]. Napa, CA; Dey; March 2011.
73 Combivent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; April 2011.
74 Atrovent [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; March 2002.
75 Atrovent HFA [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; December 2010.
76 Daliresp [package insert]. St. Louis, MO; Forest Laboratories; February 2011.
77 Spiriva [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; December 2009.
80 Daliresp [package insert]. St. Louis, MO; Forest Laboratories; February 2011.
93 Daliresp [package insert]. St. Louis, MO; Forest Laboratories; February 2011.